Home >Science >Health >China targets to produce 61 crore doses of covid vaccines this year
SinoVac is developing one of China’s top four vaccine candidates along with state-owned SinoPharm
SinoVac is developing one of China’s top four vaccine candidates along with state-owned SinoPharm

China targets to produce 61 crore doses of covid vaccines this year

  • Earlier this year, China permitted emergency use of vaccine candidates for at-risk populations like border personnel and medical workers

China's annual production capacity of COVID-19 vaccines is expected to reach 610 million doses by end-2020, the country's National Health Commission said today.

Production capacity of the vaccines is forecast to reach 1 billion doses per year by 2021, Zheng Zhongwei, director General of the Development Centre for Medical Science and Technology of the commission, told a news briefing.

A Chinese pharmaceutical company on Thursday said the coronavirus vaccine it is developing should be ready by early 2021 for distribution worldwide, including the United States.

Yin Weidong, the CEO of SinoVac, vowed to apply to the U.S. Food and Drug Administration to sell CoronaVac in the United States if it passes its third and final round of testing in humans. Yin said he personally has been given the experimental vaccine.

SinoVac is developing one of China’s top four vaccine candidates along with state-owned SinoPharm, which has two in development, and military-affiliated private firm CanSino.

More than 24,000 people are participating in clinical trials of CoronaVac in Brazil, Turkey, and Indonesia, with additional trials scheduled for Bangladesh and possibly Chile, Yin said.

SinoVac is also starting to test small doses of CoronaVac on children and the elderly in China after noticing rising numbers of cases globally among those two groups.

Yin said the company would prioritize distribution of the vaccine to countries hosting human trials of CoronaVac.

While the vaccine has not yet passed the phase 3 clinical trials, a globally accepted standard, SinoVac has already injected thousands of people in China under an emergency use provision.

Yin said he was one of the first to receive the experimental vaccine months ago along with researchers after phase one and two of human trials showed no serious adverse effects. He said that self-injecting showed his support for CoronaVac.

Earlier this year, China permitted “emergency use" of vaccine candidates for at-risk populations like border personnel and medical workers if companies could show “good safety and good antibodies" from tests of about 1,000 people, Yin said.

SinoVac received that approval in June along with SinoPharm and CanSino, and was able to provide tens of thousands of doses of CoronaVac to Beijing's municipal government, Yin said.

SinoVac employees qualified for emergency use of the vaccine because an outbreak inside the company would cripple its ability to develop a vaccine, he said. About 90% of the company’s staff have received it.

“We are confident that our research of the COVI-19 vaccines can meet the standards of the U.S. and EU countries," Yin said.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
x
×
My Reads Redeem a Gift Card Logout